Form 4 for KRYS Krystal Biotech, Inc.
Accepted 2023-06-09 00:00:00 ET · period of report 2023-06-08 · accession 0001711279-23-000046 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| MI | 2023-06-09 | 2023-06-08+ | KRYS | JANNEY DANIEL | Dir | S - Sale | $128.36 | -50.0K | 126.3K | -28% | -$6.42M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-09 | S | D | 3,935 | $129.29 | 122,362 | I Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F5) The transaction was executed in multiple trades ranging from $129.0000 to $129.7400. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F1) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 2 | Common | Common Stock | 2023-06-09 | S | D | 5,000 | $128.84 | 117,362 | I Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F6) The transaction was executed in multiple trades ranging from $128.5000 to $129.4800. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F1) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 3 | Common | Common Stock | 2023-06-09 | S | D | 10,000 | $128.53 | 107,362 | I Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F7) The transaction was executed in multiple trades ranging from $127.715 to $129.6100. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F1) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 4 | Common | Common Stock | 2023-06-08 | S | D | 4,604 | $127.96 | 152,758 | I Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F1) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 5 | Common | Common Stock | 2023-06-08 | S | D | 1,073 | $129.02 | 151,685 | I Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F2) The transaction was executed in multiple trades ranging from $129.0000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F1) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 6 | Common | Common Stock | 2023-06-08 | S | D | 5,388 | $128.73 | 146,297 | I Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F3) The transaction was executed in multiple trades ranging from $128.5000 to $129.0600. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F1) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 7 | Common | Common Stock | 2023-06-08 | S | D | 5,000 | $127.96 | 141,297 | I Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F1) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 8 | Common | Common Stock | 2023-06-08 | S | D | 10,000 | $127.96 | 131,297 | I Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F1) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |
| 9 | Common | Common Stock | 2023-06-08 | S | D | 5,000 | $127.86 | 126,297 | I Directly beneficially owned by Alta Bioequities, L.P. | — | — | (F4) The transaction was executed in multiple trades ranging from $127.7000 to $128.44. The price reported above reflects the weighted average sale price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range set forth herein. (F1) Alta Bioequities Management, LLC is the general partner of Alta Bioequities, L.P. and may be deemed to have sole voting and investment power over the shares beneficially owned by Alta Bioequities, L.P. The Reporting Person is the Managing Director of Alta Bioequities Management, LLC. The Reporting Person disclaims beneficial ownership of such shares except to the extent of his pecuniary interest therein. |